• Merck posted a press release on Phase 3 ISLEND-1 and ISLEND-2 data for once-weekly oral islatravir/lenacapavir in virologically suppressed adults with HIV.
• Week 48 endpoint met, showing noninferior viral suppression versus BIKTARVY in ISLEND-1, versus daily standard-of-care regimens in ISLEND-2.
• Results are slated for late-breaking presentation at AIDS 2026 on July 29, forming the basis for regulatory filings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief on July 21, 2026, and is solely responsible for the information contained therein.